AIM: To investigate the expression of Neurensin-2 (NRSN2) in hepatocellular carcinoma (HCC) and its prognostic values in predicting survival. METHODS: The expression and prognostic significance of NRSN2 in HCC was examined by performing immunohistochemical analysis using a total of 110 HCC clinical tissue samples, and Western blotting analysis to further confirm the result. RESULTS: Decreased NRSN2 expression was shown in 70.9% cases. Loss of NRSN2 expression in HCC was significantly related to tumor size (P = 0.006). Larger tumor size was related to negative expression of NRSN2. Patients showing negative NRSN2 expression had a significantly shorter overall survival than those with positive expression (P = 0.008). Multivariate Cox regression analysis indicated that NRSN2 expression level was an independent factor of survival (P = 0.013). Western blotting analysis further confirmed decreased expression of NRSN2 in tumor tissues compared with non-tumorous tissues. CONCLUSION: Our study indicated that NRSN2 could be a tumor suppressor gene for HCC and a candidate biomarker for long-term survival in HCC.
AIM: To investigate the expression of Neurensin-2 (NRSN2) in hepatocellular carcinoma (HCC) and its prognostic values in predicting survival. METHODS: The expression and prognostic significance of NRSN2 in HCC was examined by performing immunohistochemical analysis using a total of 110 HCC clinical tissue samples, and Western blotting analysis to further confirm the result. RESULTS: Decreased NRSN2 expression was shown in 70.9% cases. Loss of NRSN2 expression in HCC was significantly related to tumor size (P = 0.006). Larger tumor size was related to negative expression of NRSN2. Patients showing negative NRSN2 expression had a significantly shorter overall survival than those with positive expression (P = 0.008). Multivariate Cox regression analysis indicated that NRSN2 expression level was an independent factor of survival (P = 0.013). Western blotting analysis further confirmed decreased expression of NRSN2 in tumor tissues compared with non-tumorous tissues. CONCLUSION: Our study indicated that NRSN2 could be a tumor suppressor gene for HCC and a candidate biomarker for long-term survival in HCC.
Authors: Jose M Silva; Mamie Z Li; Ken Chang; Wei Ge; Michael C Golding; Richard J Rickles; Despina Siolas; Guang Hu; Patrick J Paddison; Michael R Schlabach; Nihar Sheth; Jeff Bradshaw; Julia Burchard; Amit Kulkarni; Guy Cavet; Ravi Sachidanandam; W Richard McCombie; Michele A Cleary; Stephen J Elledge; Gregory J Hannon Journal: Nat Genet Date: 2005-10-02 Impact factor: 38.330
Authors: L Zender; W Xue; C Cordón-Cardo; G J Hannon; R Lucito; S Powers; P Flemming; M S Spector; S W Lowe Journal: Cold Spring Harb Symp Quant Biol Date: 2005
Authors: Michael T Hemann; Jordan S Fridman; Jack T Zilfou; Eva Hernando; Patrick J Paddison; Carlos Cordon-Cardo; Gregory J Hannon; Scott W Lowe Journal: Nat Genet Date: 2003-02-03 Impact factor: 38.330
Authors: Lars Zender; Mona S Spector; Wen Xue; Peer Flemming; Carlos Cordon-Cardo; John Silke; Sheung-Tat Fan; John M Luk; Michael Wigler; Gregory J Hannon; David Mu; Robert Lucito; Scott Powers; Scott W Lowe Journal: Cell Date: 2006-06-30 Impact factor: 41.582